Coatings for supplements and related methods
A coating composition with a polymer, moisture barrier, and calcium carbonate addresses the stability issues of SAMe tablets by ensuring rapid absorption and stability against moisture, enhancing the efficacy of SAMe-containing tablets.
Patent Information
- Application Number
- JP2024532284
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-08
- Filing Date
- 2022-12-07
- Publication Date
- 2024-11-21
AI Technical Summary
Existing SAMe-containing tablets with enteric coatings suffer from slower moisture absorption and higher humidity sensitivity, leading to expansion and degradation of the tablet core, which compromises the stability and efficacy of the active ingredients.
A coating composition comprising a polymer or resin, moisture barrier, calcium carbonate, and plasticizer is applied to the tablet, forming a partially hydrophobic layer that degrades at both acidic and neutral pH, allowing rapid absorption of SAMe and other hydroscopic/hygroscopic materials.
The coating provides enhanced stability against moisture and humidity, ensuring rapid ingredient absorption and reduced variability, maintaining the integrity and efficacy of SAMe and other hydroscopic/hygroscopic materials.
Smart Images

Figure 2024543566000001
Abstract
Description
[Technical field]
[0001] This international (PCT) patent application claims priority to U.S. Provisional Patent Application No. 63 / 287,114, filed December 8, 2021, which is incorporated herein by reference in its entirety.
[0002] The present invention relates generally to coating supplements, such as human or veterinary supplements, and methods for making such supplements.
[0003] Nutritional supplements for oral administration to humans and animals such as dogs, cats, or horses can be provided as tablets. SAMe (S-adenosylmethionine) is an example of a nutritional supplement that can be provided as a tablet. SAMe is known to be able to maintain the liver and keep the liver functioning properly in animals. Specifically, it has long been known that SAMe can significantly increase hepatic levels of glutathione, a compound important for liver health. Glutathione is produced during the metabolism of SAMe. SAMe can also protect liver cells from cell death, as well as aid in cell repair and cell regeneration. SAMe can also be administered to animals to treat osteoarthritis / osteoarthritis, behavioral changes, and other cognitive and neurological disorders.
[0004] SAMe-containing tablets generally have an enteric coating to slow the absorption of SAMe in the animal's body. This enteric coating provides protection from the environment and is stable to the acidic pH of the stomach, but dissolves at pH levels above 5-6. Thus, the use of an enteric coating slows the release of SAMe until it enters an area with a higher pH, such as the animal's small intestine.
[0005] Generally, enteric coatings are formed from polymers or other substances with properties similar to those of polymers. Materials that have been used to form enteric coatings include resins, fatty acids, waxes, the natural resin shellac, plastics, vegetable fibers, and organic solvents. One example that has been used to form enteric coatings is methacrylic acid. However, tablets containing SAMe and methacrylic acid tend to absorb moisture slowly at room temperature and when exposed to humidity at a rate higher than expected (25°C, 60% RH). When moisture penetrates the tablet, the tablet core expands, resulting in the release or leaching of tablet ingredients or the tablet core softening. There is a need for coated tablets containing SAMe that remain hard to the touch when exposed to moisture. Summary of the Invention
[0006] One aspect of the present invention provides a film-coated tablet for human or veterinary use, the tablet comprising SAMe, milk thistle and / or any other hydroscopic or hygroscopic raw material.
[0007] In one embodiment, the coating of the coated tablet comprises a polymer or resin, stearic acid, and calcium carbonate.
[0008] In another embodiment, the coating of the coated tablet comprises a polymer or resin, a moisture barrier, calcium carbonate, and a plasticizer.
[0009] Yet another embodiment provides a method for producing coated tablets containing SAMe, milk thistle and / or any other hydroscopic or hygroscopic ingredient, in which a coating is applied to uncoated tablets containing SAMe, milk thistle and / or any other hydroscopic or hygroscopic ingredient.
[0010] In one embodiment, the coating applied to an uncoated tablet comprises a polymer or resin, stearic acid, and calcium carbonate.
[0011] In another embodiment, the coating applied to the uncoated tablet comprises a polymer or resin, a moisture barrier, calcium carbonate, and a plasticizer.
[0012] In one embodiment, the present invention provides a coated tablet containing a hydroscopic or hygroscopic material such as SAMe (S-adenosylmethionine) as a nutritional supplement for oral administration to humans or animals such as dogs, cats, and horses. Generally, SAMe is administered to animals to maintain the liver and optimize liver function. More specifically, SAMe is known to significantly enhance hepatic levels of glutathione, a compound important for liver health. Glutathione is produced during the metabolism of SAMe. SAMe can also protect liver cells from cell death, as well as aid in cell repair and cell regeneration. Additionally, SAMe can be administered to animals to treat osteoarthritis / osteoarthritis, behavioral changes, and other cognitive and neurological disorders.
[0013] In an exemplary embodiment, the tablet of the present invention has approximately 90 mg to approximately 675 mg of SAMe (S-adenosylmethionine) as the active ingredient. For example, the tablet can contain approximately 90 mg of SAMe ion, 225 mg of SAMe ion, 425 mg of SAMe ion, or 675 mg of SAMe ion.
[0014] Various forms of SAMe can be present in the tablets of the present invention, for example, the tablets can contain S-adenosylmethionine tosylate disulfate (SAMe), a SAMe salt, such as 1,4-butanedisulfonate, tosylate, or ditosylate disulfate.
[0015] In addition to SAMe, the tablet may contain other active and / or inactive ingredients. A variety of different ingredients may be used depending on the intended purpose of the tablet. In one exemplary embodiment, the tablet may further contain silybin in addition to SAMe. Silybin is the active moiety of milk thistle extract, which has been shown to support liver function by helping to maintain a healthy oxidative balance.
[0016] In one exemplary embodiment, the tablet contains about 31 mg of silybin-phosphatidylcholine complex (SPC) providing about 90 mg of SAMe ion and 9 mg of silybin A+B. In another embodiment, the tablet contains about 82 mg of silybin-phosphatidylcholine complex (SPC) providing about 225 mg of SAMe ion and 24 mg of silybin A+B. In another embodiment, the tablet contains about 120 mg of silybin-phosphatidylcholine complex (SPC) providing about 425 mg of SAMe ion and 35 mg of silybin A+B. In yet another embodiment, the tablet contains about 190 mg of silybin-phosphatidylcholine complex (SPC) providing about 675 mg of SAMe ion and 56 mg of silybin A+B.
[0017] In one exemplary embodiment, the coating comprises at least a polymer or resin (which may also be referred to as a polymeric film former), a moisture barrier, and calcium carbonate. The moisture barrier is preferably stearic acid, such as purified stearic acid. The stearic acid may be present in an amount of 0.6 to 2.4% by weight based on the total weight of the uncoated tablet. The calcium carbonate may be present in an amount of 0.47 to 1.92% by weight based on the total weight of the uncoated tablet. It is believed that the combined use of stearic acid and calcium carbonate can greatly contribute to the coating's stability and beneficial properties, including moisture resistance.
[0018] The coating can contain various other ingredients. In another embodiment, the coating has at least a polymer or resin (which may also be referred to as a polymeric film former), a moisture barrier, calcium carbonate, and a plasticizer. The coating can also contain a clouding agent and / or a colorant. In one exemplary embodiment, the polymeric film former is hydroxypropyl methylcellulose, the moisture barrier is refined stearic acid, and the plasticizer is triethyl citrate and lecithin, such as sunflower lecithin. In an exemplary embodiment, lecithin is an optional ingredient. Calcium carbonate can also act as a clouding agent. The coating according to this embodiment also has caramel, but may contain various other ingredients.
[0019] In an exemplary embodiment of the coating, the amount of polymer or resin, such as hydroxypropylmethylcellulose, is 0.7-2.8% by weight, the amount of moisture barrier, such as purified stearic acid, is 0.6-2.4% by weight, the amount of calcium carbonate is 0.47-1.92% by weight, the total amount of plasticizer, such as triethyl citrate, and optional lecithin, is 0.2-0.8% by weight, and the amount of colorant, such as caramel colorant, is 0.02-0.09% by weight. All based on the total weight of the uncoated tablet (which can also be referred to as the weight gain of the coating). All solid ingredients dissolve in water and, once dissolved, are applied to the tablet.
[0020] The coating is part of a coated tablet. Generally, the amount of coating is in the range of 2% to 8% by weight, for example 4% to 5% by weight, based on the total weight of the uncoated tablet.
[0021] Unlike tablets with enteric coatings where absorption of SAMe and other hydroscopic / hygroscopic ingredients contained in the tablet is delayed until the coating is exposed to a pH range of 5-6, the coating of the present invention degrades in both acidic and neutral pH ranges. Because the coating can degrade at acidic pH, absorption of SAMe and other hydroscopic / hygroscopic ingredients contained in the tablet occurs more quickly than when an enteric coating is used. Furthermore, because the degradation occurs more quickly, there is less variability in the absorption of SAMe and other hydroscopic / hygroscopic ingredients into the bloodstream.
[0022] The present invention also relates to a method for producing a coating, in which the coating is formed by combining ingredients including at least a polymer film former, a moisture barrier, calcium carbonate, and a plasticizer, and during the production of the coating, the combined ingredients combine to form a protective layer that is partially hydrophobic.
[0023] The present invention also relates to a method for preparing coated tablets, in which the coating having SAMe, milk thistle and / or other hydroscopic or hygroscopic ingredients is applied (attached) to an uncoated tablet. The coating can be applied to the uncoated tablet using a variety of methods, including conventional standard coating pans, porous pan systems, and fluidized systems.
[0024] The coating has several effects, such as delaying or eliminating the ingress of moisture into the coated tablet. The method of forming the coating of the present invention on a tablet is simpler than the method of applying a conventional enteric coating to a tablet. Each enteric coating formulation requires a more complicated process to achieve enteric properties. In the enteric coating formation, the SAMe or other hydroscopic / hygroscopic raw material composition contained in the tablet is exposed to higher moisture and higher temperature. SAMe is sensitive to temperature and humidity, and degradation occurs. The coating of the present invention is applied (attached) to the tablet in less time than the enteric coating, and the sensitive raw materials are exposed to heat and moisture during the coating (process) for a shorter time.
[0025] [experiment] The coated tablets of the present invention were subjected to stress testing to evaluate their performance and to determine whether the coated tablets absorbed unacceptable amounts of moisture. As noted above, SAMe is susceptible to temperature and humidity, which can cause degradation. In the stress testing, the coated tablets were exposed to a temperature of 50°C for 5 days. The tablets were evaluated on days 0, 3, and 5 to compare the degree of degradation of the SAMe raw material.
[0026] Prior to stress testing, the tablets were loaded with a minimum of 425 mg of SAMe ion. The specific SAMe source loaded into the coated tablets tested was S-adenosylmethionine tosylate disulfate (SAMe), containing a minimum of 49% SAMe ion. Except for the coating, the tablets of the invention and the control tablets had the same composition.
[0027] The coating of the tablet according to the present invention (Example 1) had the above composition, specifically, a composition using hydroxypropylmethylcellulose, purified stearic acid, calcium carbonate, sunflower lecithin, triethyl citrate, and caramel coloring in combination. The amount of hydroxypropylmethylcellulose used was 0.7-2.8% by weight, the amount of purified stearic acid used was 0.6-2.4% by weight, the amount of calcium carbonate used was 0.47-1.92% by weight, the total amount of triethyl citrate and sunflower lecithin used was 0.2-0.8% by weight, and the amount of caramel coloring used was 0.02-0.09% by weight, all of which were amounts based on the total weight of the uncoated tablets. All of the coating solid components were dispersed in water at a constant solid content rate, and after uniform dispersion, the coating was applied to the tablets with an appropriate weight gain.
[0028] Two comparative coated tablets were also tested. The comparative coated tablets had a coating of methacrylic acid copolymer content of 14.2-56.81 mg, titanium dioxide content of 2.82-11.27 mg, anhydrous colloidal silica content of 0.33-1.32 mg, talc content of 3.12-12.48 mg, and triethyl citrate content of 3.29-13.16 mg. The inventive example composition and the first comparative composition were contained in a high density polyethylene (HDPE) bottle. The test results in Table 1 below show the amount of SAMe ions (mg) in the coated tablets after exposure to 50°C for 5 days.
[0029] [Table 1] Example 1 Comparative Example 1 Comparative Example 2 (2 lots) SAMe ion content 420mg 406mg 412 / 430mg
[0030] As shown in Table 1, the coated tablet of the present invention (Example 1) contained 420 mg of SAMe ion at the end of the test. The coated tablet of Comparative Example 1 contained 406 mg of SAMe ion at the end of the test, and the two coated tablets of Comparative Example 2 contained 412 mg and 430 mg of SAMe ion at the end of the test. These test results indicate that the coating of Example 1 performs as well as, if not better than, the comparative coating. The long-term stability of the coating of Example 1 continued at 25°C / 60% RH, 30°C / 65% RH, and 40°C / 75% RH during typical stability evaluations.
[0031] Although several embodiments of the present invention have been described above, all of them are for illustrative purposes and are not intended to be limiting or restrictive. Various modifications are possible in light of the above description. These embodiments are selected by those skilled in the art so that the description of the embodiments can be utilized, and various modifications can be made according to the intended specific use. Any such modifications are intended to be included within the scope of the present disclosure.
Claims
1. Tablets having SAMe (S-adenosylmethionine), milk thistle, and / or other hygroscopic ingredients, and a coating having a polymer or resin, stearic acid, and calcium carbonate; A coated tablet for human or animal use comprising:
2. 2. The coated tablet of claim 1, wherein the stearic acid is present in an amount of 0.6 to 2.4% by weight and the calcium carbonate is present in an amount of 0.47 to 1.92% by weight, based on the total weight of the uncoated tablet.
3. 2. The coated tablet according to claim 1, wherein the coating is partially hydrophobic.
4. Tablets having SAMe (S-adenosylmethionine), milk thistle, and / or other hygroscopic ingredients, and A coating having a polymer or resin, a moisture barrier, calcium carbonate and a plasticizer; A coated tablet for human or animal use comprising:
5. 5. The coated tablet of claim 4, wherein the polymer or resin is present in an amount of 0.7 to 2.8% by weight, the moisture barrier is present in an amount of 0.6 to 2.4% by weight, the calcium carbonate is present in an amount of 0.47 to 1.92% by weight, and the plasticizer is present in an amount of 0.2 to 0.8% by weight, based on the total weight of the uncoated tablet.
6. 5. The coated tablet of claim 4, wherein said moisture barrier is purified stearic acid.
7. 5. The coated tablet of claim 4, wherein said polymer or resin is hydroxypropyl methylcellulose, said moisture barrier is purified stearic acid, and said plasticizer comprises triethyl citrate.
8. The coated tablet of claim 7, wherein the plasticizer further comprises lecithin.
9. The coated tablet according to claim 4, further comprising a colorant.
10. 10. The coated tablet of claim 9, wherein the polymer or resin is hydroxypropyl methylcellulose, the moisture barrier is refined stearic acid, the plasticizer comprises triethyl citrate and lecithin, and the colorant comprises caramel.
11. A method for producing a coated tablet for human or animal use, the method comprising the steps of: The method includes the step of applying a coating to a tablet, The tablet comprises SAMe (S-adenosylmethionine), milk thistle and / or other hygroscopic ingredients; The coating comprises a polymer or resin, stearic acid, and calcium carbonate. A method for producing coated tablets for human or animal use.
12. The method of claim 11, wherein the stearic acid is present in an amount of 0.6 to 2.4% by weight and the calcium carbonate is present in an amount of 0.47 to 1.92% by weight, based on the total weight of the uncoated tablet.
13. The method of claim 11 , wherein the coating is partially hydrophobic.
14. A method for producing a coated tablet for human or animal use, the method comprising the steps of: The method includes the step of applying a coating to a tablet, The tablet comprises SAMe (S-adenosylmethionine), milk thistle and / or other hygroscopic ingredients; The coating comprises a polymer or resin, a moisture barrier, calcium carbonate, and a plasticizer. A method for producing coated tablets for human or animal use.
15. 15. The process of claim 14, wherein the polymer or resin is present in an amount of 0.7 to 2.8 wt%, the moisture barrier is present in an amount of 0.6 to 2.4 wt%, the calcium carbonate is present in an amount of 0.47 to 1.92 wt%, and the plasticizer is present in a combined amount of 0.2 to 0.8 wt%, based on the total weight of the uncoated tablet.
16. The method of claim 14, wherein the moisture barrier is purified stearic acid.
17. 15. The method of claim 14, wherein the polymer or resin is hydroxypropyl methylcellulose, the moisture barrier is purified stearic acid, and the plasticizer comprises triethyl citrate.
18. 20. The method of claim 17, wherein the plasticizer further comprises lecithin.
19. The method of claim 14 further comprising a colorant.
20. 20. The method of claim 19, wherein the polymer or resin is hydroxypropyl methylcellulose, the moisture barrier is refined stearic acid, the plasticizer comprises triethyl citrate and lecithin, and the colorant comprises caramel.
Citation Information
Patent Citations
Film coating formula containing calcium carbonate, usage method thereof and purpose thereof
CN102295788A
